Clinical Trials Europe 2022
Join us at the annual CTE in Amsterdam where they welcome the next generation of clinical trials. The agenda is packed with highlights in technology and innovation, diversity, partnerships, and much more. Come listen to expert panelists as they discuss emerging best practices in decentralized clinical trials, share updates in regulations, and hear the perspectives from industry leaders from around the world.
Stop by our booth #40 and see a demo to find out how our solutions can enrich your clinical trial data!
Session 1 Information:
Panel: Looking into the Clinical Future: What Will Stay Post Pandemic?
Date: Monday, November 7th, 2022
Time: 5:10 p.m. – 5:50 p.m. CET/CEST
- Post-Pandemic: What’s going to stick and what’s not?
- Will the change outlast the pandemic?
- Does the decentralized approach enhance diversity and inclusion? What are the metrics required to measure these changes?
- What regulatory changes will be in place post-pandemic
- What is the next version of DCT going to look like?
- The collection and use of public/patient data
Panelist
Chris Fikry
President and Chief Executive Officer at Clario
Chris brings nearly two decades of leadership in the life sciences industry to his role as President and Chief Executive Officer (CEO) at Clario. He believes in strong collaboration with customers to shape the future of medicine and medical device development using Clario’s technology and scientific expertise and is committed to supporting Clario customers in their efforts to bring new medicines to patients faster, more safely and more cost effectively. Having served as President of Analytical Services Division at Thermo Fisher Scientific and Vice President at PPD, Quest Diagnostics and Novartis, he has the deep knowledge and expertise required to lead the organization as it continues to evolve and strengthen its market leadership.
Additional industry panelists include:
- Moderator: Bill Hanlon, President CDCS, Clinical Therapeutic & Regulatory Science & Chief Scientific Officer at Labcorp
- Bert Hartog, Senior Director, Focus Area Lead, Janssen Clinical Innovation at Janssen R&D
- Kenneth Getz, Director & Research Professor, Tufts Center for the Study of Drug Development at Tufts University School of Medicine
- Richard Stephens, Co-Editor-in-Chief at Journal of Research Involvement and Engagement
- Janis Little, Vice President, Global R&D Quality at Moderna
- Lada Leyens, Senior Director – Regulatory Clinical Trial Innovation and Digital Health at Roche
Session 2 Information:
Let’s Get Real About DCT Operations (No Slides, No Spin, Real Talk)
Decentralized Clinical Trails Track
Date: Tuesday, November 8th, 2022
Time: 4:20 p.m. – 4:50 p.m. CET/CEST
There is a lot of information in the industry about how DCTs affect our studies, but does that translate in reality when operationalized? Clare and Bryan will involve the audience in an interactive discussion about DCT trends at the forefront within industry sectors. Join the conversation to share your insights and learn what your colleagues have to say about current industry DCT trends including:
- Designing the study first, then exploring technology to best fit the plan
- DCTs slowing down study start-up
- Regulatory agencies uncommitted to DCTs
- Challenges to changing technologies halfway through a study
Speakers
Clare Campbell
Senior Director, Enterprise DCT and Patient Centric Solutions at Labcorp
Clare Campbell is a Senior Director, Enterprise DCT and Patient Centric Solutions at Labcorp and has been in the pharmaceutical industry for 25 years. Clare’s career started in Data Management before progressing to manage Project Management and Phase I Operations at Covance CRU, Leeds. Clare has held management positions in Labcorp’s Operational Strategy and Planning and Oncology Global Project Delivery Groups. In September 2021 Clare moved to the Digital Operations division in Labcorp to focus on Connected Health solutions.
Bryan McDowell
VP, eCOA Science & Consulting at Clario
In his role as VP, eCOA Science & Consulting, Bryan brings extensive experience and expertise to achieve smarter drug development, clinical trial design and execution (including decentralized and remote trials) to vastly expand the reach and access of trials to more patients, provide improved patient experience and data quality to deliver accelerated drug & device development programs. Bryan is a thought leader and recognized strategist & visionary and continues to influence, drive and deliver on the pharma-wide industry necessity for smarter drug & device development and life cycle management.